There were no main Group differences on any of the mood or performance measures at baseline (before dosing). However, a few measures showed a significant effect of Phase or a Group × Phase interaction at baseline. Specifically, scores on the Beck Depression Inventory [F(1,43) = 4.53; p <0.05], the Depression-Dejection subscale of the POMS [F(1,43) = 3.95; p <0.053], and the Bad Drug Effect cluster [F(1,43) = 9.25; p <0.01]were significantly higher in the luteal phase compared to the follicular phase. There was also a significant Phase × Group interaction on the Beck Depression Inventory [F(1,43) = 4.05; p <0.05] and the Tension-Anxiety subscale of the POMS [F(1,43) = 5.81; p <0.03] in that FHP women were more depressed and anxious during the luteal phase compared to FHN women. Similar trends were observed on the State Anxiety scale (p<0.09), and the Friendly subscale of the POMS (p<0.07), in that FHP women reported more dysphoric effects in the luteal phase compared to FHN women at baseline.
